Project Grant R01CA281075
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$433K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
The Johns Hopkins University was awarded a $431,561 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research aimed at elucidating the role of the HMGA1 chromatin regulator in pancreatic ductal adenocarcinoma (PDAC) progression and the tumor microenvironment (TME). The research project seeks to precisely define HMGA1-dependent mechanisms in PDAC tumor progression using mouse models and primary human tumors, as well as...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $485,558 over 5 years to The General Hospital Corporation (Massachusetts General Hospital) for a study on a novel glutathione-dependent metabolic pathway that drives metastatic outgrowth in pancreatic cancer. The research aims to molecularly characterize key factors involved in this pathway, with the potential to develop new diagnostic markers and therapeutic strategies for treating...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $622,548 in funding to the University of Pittsburgh to investigate the role of the nervous system in pancreatic cancer progression.
The key products and services to be delivered under this five-year award include:
Examining how sensory nerves and neuronally-expressed immune checkpoint proteins impact immune cell functions and tumor growth within the pancreatic tumor...
The National Cancer Institute (NCI) awarded a $269,280 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Translational Genomics Research Institute (TGen), a non-profit biomedical research organization, to conduct preclinical research on targeting cellular senescence in pancreatic ductal adenocarcinoma (PDAC). The grant aims to determine the biological effects of a senescent cell-targeted antibody, SIWA318, and evaluate its ability to improve the efficacy of standard-of-care...
This $578,998 Project Grant award from the National Cancer Institute (under CFDA 93.395 - Cancer Treatment Research) aims to develop a novel targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC). The key objectives are to:
Determine the mechanisms by which the cancer-specific Tn antigen enhances PDAC tumor progression and identify Tn-expressing glycoproteins through advanced glycoproteomics analysis in mouse models and clinical samples.
Validate the role...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sanford Burnham Prebys Medical Discovery Institute to investigate macropinocytosis as a metabolic adaptation in pancreatic cancer cells treated with the glutamine mimetic 6-diazo-5-oxo-L-norleucine (DON). The $561,077 award, spanning July 2024 to June 2029, aims to elucidate the role of the WNK4 kinase in regulating macropinocytosis and...
This federal Project Grant award of $436,431 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to target metabolic crosstalk in pancreatic ductal adenocarcinoma (PDA). The University of California, Irvine is the prime awardee, conducting fundamental investigations into mechanisms that maintain cancer cell heterogeneity and metabolic symbiosis in PDA tumors. The research aims to identify oncogenic and stress pathways that can be targeted to...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding research at Northwestern University to investigate the potential role of cancer-induced deficiencies in the intestinal vasculature and lymphatics as an underlying cause of cancer-associated cachexia. The $502,563 award, which began on July 5, 2024 and runs through June 30, 2029, aims to determine if targeting vascular and lymphatic barrier dysfunction can be used to reverse...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $622,984 to the University of California, Los Angeles (UCLA) to conduct a multi-year systems metabolic approach for characterizing and imaging pancreatic cancer phenotypes. The key objectives are to:
Integrate multi-scale measurements from cell, tissue, and organ levels with advanced imaging modalities (PET/CT) to establish definitive phenotypes of pancreatic...
The National Cancer Institute (NCI) awarded a 5-year, $659,090 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Johns Hopkins University to develop a mutant KRAS-targeted vaccine for the interception of pancreatic cancer development. The research aims to:
Evaluate the safety and immunogenicity of the KRAS vaccine in individuals with genetic predisposition and high-risk pre-cancerous lesions. This includes studying KRAS-specific T cell responses, repertoire, and...